DK2437739T3 - Glomerulonephritis-TREATMENT - Google Patents

Glomerulonephritis-TREATMENT Download PDF

Info

Publication number
DK2437739T3
DK2437739T3 DK10722643.3T DK10722643T DK2437739T3 DK 2437739 T3 DK2437739 T3 DK 2437739T3 DK 10722643 T DK10722643 T DK 10722643T DK 2437739 T3 DK2437739 T3 DK 2437739T3
Authority
DK
Denmark
Prior art keywords
compound
group
glomerulonephritis
use according
treatment
Prior art date
Application number
DK10722643.3T
Other languages
Danish (da)
English (en)
Inventor
Berit Johansen
Andrea Huwiler
Original Assignee
Avexxin As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avexxin As filed Critical Avexxin As
Application granted granted Critical
Publication of DK2437739T3 publication Critical patent/DK2437739T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/227—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK10722643.3T 2009-06-04 2010-06-04 Glomerulonephritis-TREATMENT DK2437739T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0909643A GB0909643D0 (en) 2009-06-04 2009-06-04 Glomerulonephritis treatment
PCT/EP2010/003384 WO2010139482A1 (en) 2009-06-04 2010-06-04 Glomerulonephritis treatment

Publications (1)

Publication Number Publication Date
DK2437739T3 true DK2437739T3 (en) 2015-08-17

Family

ID=40936918

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10722643.3T DK2437739T3 (en) 2009-06-04 2010-06-04 Glomerulonephritis-TREATMENT
DK14158421.9T DK2745837T3 (en) 2009-06-04 2010-06-04 Glomerulonephritis treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14158421.9T DK2745837T3 (en) 2009-06-04 2010-06-04 Glomerulonephritis treatment

Country Status (14)

Country Link
US (3) US20120136066A1 (enExample)
EP (2) EP2437739B1 (enExample)
JP (1) JP5837481B2 (enExample)
AU (1) AU2010256013B2 (enExample)
CA (1) CA2764465C (enExample)
CY (1) CY1118269T1 (enExample)
DK (2) DK2437739T3 (enExample)
ES (2) ES2546198T3 (enExample)
GB (1) GB0909643D0 (enExample)
HU (2) HUE027050T2 (enExample)
LT (1) LT2745837T (enExample)
PL (2) PL2745837T3 (enExample)
PT (2) PT2745837T (enExample)
WO (1) WO2010139482A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201014633D0 (en) * 2010-09-02 2010-10-13 Avexxin As Rheumatoid arthritis treatment
GB201205394D0 (en) 2012-03-27 2012-05-09 Adlens Ltd Improvements in or relating to deformable non-round membrane assemblies
GB201221329D0 (en) * 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
GB201313238D0 (en) 2013-07-24 2013-09-04 Avexxin As Process for the preparation of a polyunsaturated ketone compound
GB201409363D0 (en) 2014-05-27 2014-07-09 Avexxin As Skin cancer treatment
GB201501144D0 (en) 2015-01-23 2015-03-11 Avexxin As Process for the preparation of a polyunsaturated ketone compound
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
WO2018055062A1 (en) 2016-09-21 2018-03-29 Avexxin As Pharmaceutical composition
US20220257531A1 (en) * 2017-06-16 2022-08-18 Avexxin As Compositions and methods for treatment of a fibrotic disease
GB201910644D0 (en) 2019-07-25 2019-09-11 Coegin Pharma As Cancer Treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670465A (en) * 1986-05-21 1987-06-02 Syntex (U.S.A.) Inc. Arachidonic acid analogs
JPH0987176A (ja) * 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
JPH09268153A (ja) 1996-04-02 1997-10-14 Sagami Chem Res Center トリフルオロメチルケトン誘導体及びホスホリパーゼａ２阻害剤
CA2251780A1 (en) * 1996-04-12 1997-10-23 Peptide Technology Pty. Limited Methods of treating immunopathologies using polyunsaturated fatty acids
US6107334A (en) 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
AU4994899A (en) 1998-07-13 2000-02-01 University Of South Florida Modulation of the phospholipase a2 pathway as a therapeutic
US6031014A (en) * 1998-12-08 2000-02-29 Crivello; James V. Initiator compositions and methods for their synthesis and use
WO2002060535A1 (en) * 2001-01-31 2002-08-08 Leff Alan R Method of treating inflammatory conditions by inhibiting cytosolic phospholipase a¿2?
GB0202002D0 (en) * 2002-01-29 2002-03-13 Leiv Eiriksson Nyotek A S Use
MY131170A (en) * 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
RU2356247C2 (ru) * 2003-03-18 2009-05-27 Новартис Аг Комбинации и композиции, содержащие жирные кислоты и аминокислоты, их применение для предупреждения, замедления прогрессирования или лечения диабета и связанных с диабетом заболеваний и состояний, способ снижения веса тела млекопитающего, набор
NZ552238A (en) * 2006-12-20 2009-07-31 Seperex Nutritionals Ltd An extract
US20100144827A1 (en) 2006-12-20 2010-06-10 Medwell Laboratories Ltd. C/O Ngt Technological Incubator Novel conjugates of polyunsaturated fatty acids with amines and therapeutic uses thereof
WO2009061208A1 (en) * 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament

Also Published As

Publication number Publication date
AU2010256013A1 (en) 2012-01-12
EP2745837A1 (en) 2014-06-25
EP2437739A1 (en) 2012-04-11
HUE027050T2 (en) 2016-08-29
WO2010139482A1 (en) 2010-12-09
US20120136066A1 (en) 2012-05-31
ES2546198T3 (es) 2015-09-21
PL2745837T3 (pl) 2017-01-31
DK2745837T3 (en) 2016-08-29
AU2010256013B2 (en) 2013-05-16
JP2012528813A (ja) 2012-11-15
US20140256824A1 (en) 2014-09-11
LT2745837T (lt) 2016-10-25
CY1118269T1 (el) 2017-06-28
GB0909643D0 (en) 2009-07-22
EP2745837B1 (en) 2016-07-27
US8796251B2 (en) 2014-08-05
HUE030085T2 (en) 2017-04-28
US20100311843A1 (en) 2010-12-09
ES2587719T3 (es) 2016-10-26
CA2764465C (en) 2018-03-20
CA2764465A1 (en) 2010-12-09
JP5837481B2 (ja) 2015-12-24
PT2437739E (pt) 2015-10-12
EP2437739B1 (en) 2015-07-29
PT2745837T (pt) 2016-08-22
PL2437739T3 (pl) 2015-11-30
US9187396B2 (en) 2015-11-17

Similar Documents

Publication Publication Date Title
DK2437739T3 (en) Glomerulonephritis-TREATMENT
AU2011298340B2 (en) Rheumatoid arthritis treatment using polyunsaturated long chain ketones
US8389736B2 (en) Compounds having activity in correcting mutant-CFTR processing and uses thereof
JP2006508986A (ja) ヒストンデアセチラーゼ阻害剤による肺細胞の治療方法
HUP0102782A2 (hu) NF-KB transzkripciós faktor inhibítor hatású szalicil-anilidek
JP7184241B2 (ja) ベンズヒドリルチオアセトアミド化合物を有効成分として含む線維化疾患の治療用組成物
CN106955281A (zh) 预防或减少癌发生或氧化性应激的方法
KR102602998B1 (ko) 억제제 및 이의 사용
CN106659701A (zh) 用于治疗年龄相关性症状和疾病的酮基丁酸酯化合物和组合物
WO2008006276A1 (fr) INHIBITEUR À PETITE MOLÉCULE POUVANT INHIBER LA FIBROSE DU POLYPEPTIDE Aβ DANS LA MALADIE D'ALZHEIMER, PROCÉDÉS DE PRÉPARATION CORRESPONDANTS, COMPOSITIONS PHARMACEUTIQUES ET UTILISATIONS CORRESPONDANTES
CN117242076A (zh) 基于噻吩的化合物及其作为bckdk抑制剂的用途
WO2021104507A1 (zh) 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
WO2015064447A1 (ja) フラタキシン増強剤
WO2017170860A1 (ja) ヒートショックプロテイン４７阻害剤
CN106946851B (zh) 一种用于预防和治疗肾结石的药物
WO2019159868A1 (ja) 大腸炎改善剤
TW201943716A (zh) 吳茱萸次鹼類似物及其應用
JP2017081866A (ja) 線維症の治療剤又は予防剤